Recombinant Staphylococcus epidermidis Multidrug resistance efflux pump sepA (sepA)

What is sepA in Staphylococcus epidermidis and what is its primary function?

SepA in Staphylococcus epidermidis is a multidrug efflux pump belonging to the small multidrug resistance (SMR) antibiotic efflux pump family. Its primary function is to confer resistance to disinfecting agents and dyes, particularly acriflavine, by actively pumping these compounds out of the bacterial cell, thus reducing their antimicrobial effect . The gene was first characterized in Staphylococcus aureus as a novel chromosomal drug efflux gene and has since been identified in numerous Staphylococcus species . SepA operates through antibiotic efflux mechanisms, functioning as an efflux pump complex or subunit that contributes significantly to antimicrobial resistance . This mechanism is particularly important in healthcare settings where disinfectants and antiseptics are routinely used.

In addition to its role in antimicrobial resistance, SepA also functions as a metalloprotease involved in biofilm formation. Research has demonstrated that SepA is required for Aap-dependent S. epidermidis biofilm formation in both static and dynamic biofilm models . This dual functionality makes SepA an important factor in S. epidermidis pathogenicity, particularly in medical device-associated infections where biofilm formation is a critical virulence mechanism.

How does sepA contribute to antimicrobial resistance in S. epidermidis?

SepA contributes to antimicrobial resistance in S. epidermidis through several mechanisms. Studies have shown that exposure to ethidium bromide (EtBr), a substrate of multidrug efflux pumps, led to a gradual increase in resistance to antimicrobials in S. epidermidis . The final EtBr-adapted strain displayed phenotypic resistance to fluoroquinolones and reduced susceptibility to several antiseptics and disinfectants, though interestingly without mutations in the QRDR of the grlA/gyrA genes . This suggests that the resistance mechanism was primarily efflux-based rather than target-based.

When efflux inhibitors were introduced, researchers observed a reduction in the MICs (Minimum Inhibitory Concentrations) of fluoroquinolones and selected biocides . This finding provides strong evidence for the role of efflux pumps, including SepA, in mediating antimicrobial resistance. Gene expression assays have revealed a temporal activation pattern of S. epidermidis efflux pumps, with an early response involving norA, SE2010, and SE1103, followed by a late response mediated by norA . This activation coincided with the occurrence of the mutation -1A→T in the norA promoter region, suggesting coordinated regulation of efflux pump expression.

Most significantly, research has demonstrated that S. epidermidis has the potential to develop a multiple resistance phenotype mediated by efflux when exposed to non-antibiotic substrates of multidrug efflux pumps . This finding has important implications for understanding how antimicrobial resistance can develop even in the absence of direct antibiotic pressure, potentially through exposure to disinfectants and other non-antibiotic antimicrobials commonly used in healthcare settings.

What is the relationship between sepA and biofilm formation in S. epidermidis?

SepA plays a critical role in biofilm formation in S. epidermidis, particularly in strains that do not produce polysaccharide intercellular adhesin (PIA). Research has shown that SepA is required for Aap-dependent S. epidermidis biofilm formation in both static and dynamic biofilm models . This relationship is particularly important because while many S. epidermidis strains rely on PIA for biofilm formation, studies have reported that at least 30% of invasive isolates lack the icaADBC operon for PIA biosynthesis .

In a rat central venous catheter model of S. epidermidis infection, researchers found that an ica mutant (lacking PIA) had no defect, while a single mutant lacking Aap was severely attenuated . This finding underscores the importance of Aap in biofilm formation and, by extension, the critical role of SepA in processing Aap to its biofilm-promoting form. This represents a novel role for a secreted staphylococcal protease as a requirement for biofilm development, demonstrating how protease expression levels can modulate adhesive S. epidermidis surface properties, biofilm formation, and surface colonization.

How is sepA regulated in S. epidermidis?

SepA in S. epidermidis is under tight regulation, with the global regulator SarA playing a key role. Under standard growth conditions, quantitative RT-PCR (qRT-PCR) and protease activity assays have demonstrated that sepA is repressed by SarA . This repression represents an important control mechanism that links general regulatory networks to specific effector proteins involved in biofilm development and antimicrobial resistance.

When SarA is inactivated (via sarA mutation), there is an increase in SepA production, which in turn augments biofilm formation . Genetic and biochemical analyses have demonstrated that this SepA-related induction of biofilm accumulation results from enhanced Aap processing . This regulatory relationship creates an interesting situation where the absence of a global regulator (SarA) leads to increased expression of sepA, which then enhances biofilm formation through increased proteolytic processing of Aap.

The repression of sepA by SarA under standard conditions suggests that sepA expression may be induced under specific environmental or stress conditions when its activity becomes beneficial for bacterial survival. This conditional expression pattern is consistent with the role of efflux pumps in responding to antimicrobial challenges and suggests that sepA regulation may be part of a broader adaptive response to environmental stressors.

What experimental approaches are most effective for studying sepA-mediated efflux in S. epidermidis?

Several experimental approaches have proven effective for studying sepA-mediated efflux in S. epidermidis, each with specific advantages for addressing different aspects of sepA function:

• Step-wise adaptation to efflux pump substrates: This approach, as used in studies with ethidium bromide (EtBr), allows researchers to observe the gradual development of resistance and associated changes in efflux pump expression and activity . The resulting EtBr-adapted strains can be characterized for their antibiotic and biocide susceptibility through MIC determination and evaluation of efflux activity .

• MIC determination with and without efflux inhibitors: Comparing the MICs of antimicrobials in the presence and absence of known efflux inhibitors provides evidence for efflux-mediated resistance . A significant reduction in MIC in the presence of inhibitors suggests active efflux involving sepA and potentially other efflux systems.

• Real-time fluorometry: This technique allows direct measurement of efflux activity by monitoring the accumulation or efflux of fluorescent substrates like EtBr . Changes in fluorescence over time reflect the activity of efflux pumps and can be used to compare wild-type, sepA-deleted, and complemented strains.

• RT-qPCR for gene expression analysis: Quantifying sepA and other efflux pump gene expression levels helps identify temporal patterns of activation and the relative contribution of different pumps . This approach has revealed that exposure to EtBr led to a gradual increase in efflux activity and a temporal activation of different efflux pumps in S. epidermidis.

• Sequencing of regulatory regions: Identification of mutations in promoter regions (like the -1A→T mutation observed in the norA promoter) can provide insights into the mechanisms of altered gene expression . This approach is particularly valuable for understanding the genetic basis of increased efflux activity.

A comprehensive experimental approach combining these methods provides the most complete understanding of sepA-mediated efflux in S. epidermidis and its contribution to antimicrobial resistance and biofilm formation.

How does sepA interact with Aap to promote biofilm formation?

The interaction between SepA and Aap (Accumulation associated protein) in promoting biofilm formation involves a complex proteolytic mechanism. SepA functions as a metalloprotease that specifically cleaves Aap at defined sites, transforming it from a form that inhibits aggregation to one that promotes biofilm formation .

Studies using recombinant proteins have demonstrated that SepA cleaves the A domain of Aap at residue 335 and between the A and B domains at residue 601 . This proteolytic processing is critical for Aap's function in biofilm formation. Processing primarily removes the portion N-terminal to the lectin-like domain but can also involve removal of the entire A domain . This cleavage of Aap favors bacterial aggregation and biofilm formation, representing a key step in the development of S. epidermidis biofilms.

The paradoxical nature of this interaction is notable: high SepA activity, such as observed in the absence of the repressor SarA, results in increased cleavage of Aap, which enhances rather than inhibits biofilm formation . This contradicts the general assumption that proteases typically degrade adhesins and reduce biofilm formation. Instead, SepA processing activates Aap's biofilm-promoting function.

This interaction is particularly significant in PIA-negative S. epidermidis strains (such as 1457Δica), where Aap-dependent biofilm formation becomes the primary mechanism for biofilm development . In these strains, SepA is required for biofilm formation in both static and dynamic models, highlighting the critical nature of this protease-adhesin interaction in the absence of PIA production.

How can sepA be targeted in antimicrobial research?

SepA presents several opportunities as a target in antimicrobial research, particularly for addressing biofilm-associated infections and antimicrobial resistance in S. epidermidis:

• Efflux Pump Inhibitors (EPIs): Developing specific inhibitors of SepA could enhance the efficacy of existing antimicrobials by preventing their efflux from bacterial cells. Research has already demonstrated that efflux inhibitors can reduce the MICs of fluoroquinolones and selected biocides in S. epidermidis . Targeting SepA with specific inhibitors could overcome efflux-mediated resistance to disinfectants and potentially sensitize bacteria to other antimicrobials.

• Anti-biofilm Strategies: Since SepA is required for Aap-dependent biofilm formation, inhibiting its proteolytic activity could potentially prevent or disrupt biofilms . This approach might be particularly valuable for preventing device-associated infections caused by S. epidermidis. Inhibitors that specifically block SepA's ability to cleave Aap could interfere with biofilm development without affecting other cellular processes.

• Regulatory Manipulation: Given that SepA is regulated by SarA, strategies that enhance SarA activity or mimic its repressive effect on sepA expression could potentially reduce SepA-mediated resistance and biofilm formation . Understanding and targeting the regulatory networks controlling sepA expression could provide novel approaches to controlling S. epidermidis infections.

• Combination Therapies: Combining SepA inhibitors with conventional antimicrobials or other anti-biofilm agents could provide synergistic effects. By simultaneously targeting multiple aspects of S. epidermidis virulence and resistance, such combination approaches might be more effective than single-agent therapies and could potentially reduce the development of resistance.

• Structure-based Drug Design: As more detailed structural information about SepA becomes available, structure-based drug design approaches could be used to develop highly specific inhibitors targeting key functional domains of the protein. This approach could lead to more effective and selective anti-SepA agents with fewer off-target effects.

How can recombinant sepA be produced and purified for in vitro studies?

Production and purification of recombinant SepA for in vitro studies requires careful consideration of its properties as a membrane protein and metalloprotease. The following methodological approach is recommended:

• Expression System Selection:

  • Escherichia coli is commonly used for recombinant protein expression due to its high yield and ease of manipulation.

  • For membrane proteins like SepA, specialized E. coli strains designed for membrane protein expression may be more suitable.

  • Expression conditions should be optimized, typically using lower temperatures (16-25°C) to enhance proper folding.

• Vector Design:

  • The sepA gene should be codon-optimized for the chosen expression system.

  • Addition of affinity tags (His-tag, GST, MBP) facilitates purification.

  • A construct similar to the "pTrcHis2::sepA" mentioned in one study, which expresses SepA with six histidines added at the N-terminus, could be used .

• Membrane Protein Extraction:

  • After cell lysis, membrane fractions are isolated by ultracentrifugation.

  • Detergents (e.g., n-dodecyl-β-D-maltopyranoside, n-octyl-β-D-glucopyranoside) are used to solubilize membrane proteins.

  • Detergent selection is critical and may require optimization specifically for SepA.

• Purification Strategy:

  • Immobilized metal affinity chromatography (IMAC) is commonly used for His-tagged proteins.

  • Size exclusion chromatography (SEC) can further purify the protein and assess its oligomeric state.

  • All buffers should contain appropriate detergent concentrations to maintain solubility.

• Quality Control:

  • SDS-PAGE and Western blotting to confirm protein identity and purity.

  • Mass spectrometry for accurate mass determination and potential post-translational modifications.

  • Functional verification using transport or protease activity assays.

This methodological approach provides a framework for producing and purifying functional recombinant SepA for detailed biochemical and structural studies. Proper characterization of the purified protein is essential to ensure that it retains both its efflux pump activity and its proteolytic function for use in in vitro studies.

What assays are most reliable for measuring sepA activity?

Measuring SepA activity requires assays that can detect both its efflux pump function and its proteolytic activity. The following assays are recommended based on the dual functionality of SepA:

For Efflux Pump Activity:

• Fluorescent Substrate Accumulation/Efflux Assays:

  • Real-time fluorometry using substrates like ethidium bromide (EtBr) or other fluorescent dyes .

  • Cells are loaded with the fluorescent substrate, and the rate of efflux is measured as a decrease in fluorescence over time.

  • This approach was successfully used in studies examining the efflux-mediated response of S. epidermidis to EtBr exposure .

• MIC Determination with Efflux Inhibitors:

  • Determining the MICs of known SepA substrates (e.g., disinfectants, acriflavine) in the presence and absence of efflux inhibitors .

  • A significant reduction in MIC in the presence of inhibitors indicates active efflux.

  • This method provides functional evidence for the role of efflux pumps in antimicrobial resistance.

For Proteolytic Activity:

• Cleavage of Recombinant Aap:

  • Incubation of purified SepA with recombinant Aap or Aap fragments .

  • Analysis of cleavage products by SDS-PAGE, Western blotting, or mass spectrometry.

  • This assay directly measures SepA's ability to process its natural substrate at the specific cleavage sites (residues 335 and 601) .

• Biofilm Formation Assays:

  • Comparison of biofilm formation between wild-type, sepA-deleted, and complemented strains .

  • Static (microtiter plate) and dynamic (flow cell) biofilm models should be used, as mentioned in the research .

  • While indirect, this assay measures the physiological outcome of SepA activity and its impact on Aap processing and biofilm formation.

For Gene Expression:

• RT-qPCR:

  • Quantification of sepA mRNA levels under different conditions .

  • This assay measures transcriptional regulation rather than activity but is valuable for understanding when SepA might be active.

  • It has been successfully used to identify temporal patterns of efflux pump gene expression in response to antimicrobial exposure .

Combining multiple assays provides the most comprehensive assessment of SepA activity and its dual role in antimicrobial resistance and biofilm formation. The selection of specific assays should be guided by the research question being addressed, with a combination of direct biochemical assays and functional biological assays providing the most robust characterization of SepA activity.

What biofilm models are most appropriate for studying sepA's role in biofilm formation?

Based on the research literature, several biofilm models are appropriate for studying sepA's role in biofilm formation in S. epidermidis. These models vary in complexity, throughput, and relevance to different clinical scenarios:

• Static Microtiter Plate Biofilm Model:

  • Research has shown that SepA is required for Aap-dependent S. epidermidis biofilm formation in static models .

  • This is a high-throughput method where bacteria are grown in 96-well plates, and biofilm formation is quantified by crystal violet staining.

  • The search results mention bacterial cultures being grown in a shaking incubator at 37°C with appropriate antibiotics, and diluted in Dulbecco's Modified Eagle Medium (DMEM) with high glucose and L-glutamine for biofilm assays .

  • Advantages: Simple, reproducible, allows screening of multiple conditions simultaneously.

  • This model is particularly useful for initial characterization and for comparing wild-type S. epidermidis strains with sepA mutants.

• Dynamic Flow Cell Biofilm Model:

  • SepA is also required for biofilm formation in dynamic models, which more closely mimic the conditions in many medical device infections .

  • Flow cells provide a continuous flow of fresh medium over developing biofilms, creating shear forces that influence biofilm structure.

  • Advantages: More physiologically relevant, allows real-time microscopic observation, better replicates the conditions found in catheter-associated infections.

  • This model is particularly valuable for detailed studies of biofilm architecture and for evaluating the effects of sepA deletion on biofilm development under flow conditions.

• Medical Device-Associated Biofilm Models:

  • Given S. epidermidis' prominence in device-associated infections, models incorporating relevant biomaterials are valuable.

  • The search results mention a rat central venous catheter model of S. epidermidis infection, where an ica mutant in strain 1457 had no defect, while a single mutant lacking Aap was severely attenuated .

  • This type of model provides the most clinically relevant setting for studying sepA's role in biofilm formation in the context of medical device infections.

  • Advantages: High clinical relevance, incorporates host factors and immune responses.

For comprehensive characterization of sepA's role in biofilm formation, a combination of these models is recommended. Begin with high-throughput static models to establish basic parameters and then progress to more complex dynamic and in vivo models to confirm relevance under more physiologically representative conditions. When comparing wild-type, sepA-deleted, and complemented strains, ensure consistent genetic backgrounds and growth conditions across all models to obtain reliable and comparable results.

How can sepA mutants be generated and characterized in S. epidermidis?

Generating and characterizing sepA mutants in S. epidermidis requires specialized molecular techniques. Based on approaches mentioned in the search results and standard methods in the field, the following methodological strategies are recommended:

Generation of sepA Mutants:

• Allelic Replacement:

  • Design a construct where the sepA coding sequence is replaced with an antibiotic resistance gene (e.g., chloramphenicol resistance gene, cat).

  • Include homologous flanking regions for recombination.

  • The search results mention a method where sepA was deleted from strains and a chloramphenicol resistance gene (cat) was inserted in place of the sepA coding sequence .

  • This approach allows for clean deletion of sepA while maintaining the expression of adjacent genes.

• CRISPR-Cas9 System:

  • Design sgRNA targeting sepA.

  • Provide a repair template with the desired mutation or deletion.

  • This approach can be more efficient than traditional allelic replacement methods.

Characterization of sepA Mutants:

This comprehensive approach to generating and characterizing sepA mutants will provide valuable insights into the dual role of SepA in antimicrobial resistance and biofilm formation in S. epidermidis, with potential implications for developing novel therapeutic strategies.

How do sepA mechanisms differ between S. epidermidis and other Staphylococcal species?

SepA is found across multiple Staphylococcus species, with the search results listing its presence in S. aureus, S. capitis, S. epidermidis, S. equorum, S. haemolyticus, S. hominis, and many others . While the core function of SepA as a multidrug efflux pump appears to be conserved across these species, there may be species-specific differences in regulation, substrate specificity, and additional functions.

In S. epidermidis, SepA has been demonstrated to have a dual role—functioning both as an efflux pump conferring resistance to disinfectants and dyes, and as a metalloprotease involved in processing Aap for biofilm formation . This dual functionality may represent a species-specific adaptation that contributes to S. epidermidis' success as a nosocomial pathogen, particularly in the context of medical device-associated infections.

The regulatory mechanism controlling sepA expression in S. epidermidis involves repression by the global regulator SarA under standard growth conditions . Whether this same regulatory mechanism exists in other Staphylococcal species remains to be fully elucidated. Species-specific differences in sepA regulation could contribute to variations in antimicrobial resistance and biofilm-forming capacity across the Staphylococcus genus.

While SepA's classification as a small multidrug resistance (SMR) antibiotic efflux pump is consistent across species, there may be differences in the specific substrates that each species' version of SepA can transport . These differences could arise from variations in the amino acid sequence within the substrate-binding regions of the protein.

Comparative genomic and functional studies across Staphylococcal species could provide further insights into the evolutionary history and selective pressures that have shaped sepA's role in different species. Such studies would be valuable for understanding how this efflux pump has been adapted to meet the specific ecological niches and antimicrobial challenges faced by different Staphylococcal species.

How does S. epidermidis sepA compare with related efflux systems in other bacterial species?

SepA in S. epidermidis belongs to the small multidrug resistance (SMR) antibiotic efflux pump family . This family of efflux pumps is found across many bacterial species, but with variations in structure, substrate specificity, and regulation. Comparing S. epidermidis sepA with related efflux systems provides insights into both conserved features and species-specific adaptations.

The search results indicate that "sepA" is also a term used for a different protein in Enteroaggregative E. coli (EAEC) strains, though this appears to be a different protein with a different function . This highlights the importance of careful terminology when discussing efflux systems across different bacterial species.

Other efflux systems in S. epidermidis, such as norA, SE2010, and SE1103, were mentioned in the search results as being activated in response to ethidium bromide exposure, alongside sepA . This suggests that S. epidermidis, like many bacteria, possesses multiple efflux systems that may have overlapping but distinct functions and substrate specificities. The temporal activation pattern observed, with an early response involving norA, SE2010, and SE1103 followed by a late response mediated by norA, indicates complex coordination among these different efflux systems .

In terms of resistance profile, SepA primarily confers resistance to disinfecting agents and dyes, including acriflavine . This substrate specificity may differ from related efflux systems in other bacterial species, which might have evolved to transport different antimicrobial compounds relevant to their ecological niches. Understanding these differences is important for developing targeted approaches to overcome efflux-mediated resistance in different bacterial pathogens.

What are the most promising approaches for inhibiting sepA to combat S. epidermidis infections?

Given SepA's dual role in antimicrobial resistance and biofilm formation, several promising approaches for inhibition could be pursued to combat S. epidermidis infections:

• Structure-Based Inhibitor Design:

  • As a member of the small multidrug resistance (SMR) family, SepA likely has structural features that could be targeted by small molecule inhibitors .

  • Detailed structural studies of SepA, including X-ray crystallography or cryo-electron microscopy, would provide the foundation for rational design of specific inhibitors.

  • Inhibitors could be designed to block either the efflux channel or the proteolytic active site, or ideally both functions simultaneously.

• Metalloprotease Inhibition:

  • Since SepA functions as a metalloprotease to cleave Aap and promote biofilm formation, specific metalloprotease inhibitors could be developed .

  • These inhibitors could target the active site responsible for cleaving Aap at residues 335 and 601, thereby preventing the processing required for biofilm formation .

  • This approach would specifically target SepA's role in biofilm formation without necessarily affecting its efflux pump activity.

• Regulatory Manipulation:

  • The finding that SepA is repressed by the global regulator SarA under standard growth conditions suggests that enhancing SarA activity could indirectly inhibit SepA .

  • Compounds that stabilize SarA or enhance its DNA-binding activity could potentially reduce sepA expression and thereby attenuate both resistance and biofilm formation.

  • This approach targets the regulatory network rather than the protein itself, potentially offering broader effects on virulence and resistance.

• Anti-Biofilm Strategies Targeting the SepA-Aap Interaction:

  • Developing compounds that specifically block the interaction between SepA and Aap without affecting other proteolytic targets could prevent biofilm formation .

  • Alternatively, developing modified versions of the Aap cleavage sites that bind to SepA but resist cleavage could act as competitive inhibitors.

  • This approach would specifically target the SepA-Aap interaction crucial for biofilm development in S. epidermidis.

• Combination Therapies:

  • Given that S. epidermidis possesses multiple efflux systems (as evidenced by the temporal activation of norA, SE2010, and SE1103 alongside sepA), combination approaches targeting multiple efflux systems simultaneously might be more effective than targeting SepA alone .

  • Similarly, combining SepA inhibitors with conventional antimicrobials could enhance efficacy against both planktonic and biofilm-associated S. epidermidis.

Each of these approaches presents unique advantages and challenges, and the most effective strategy may involve combinations of these approaches tailored to specific clinical scenarios.

What genetic factors influence sepA expression and function in clinical S. epidermidis isolates?

Understanding the genetic factors that influence sepA expression and function in clinical S. epidermidis isolates is crucial for developing targeted therapeutic strategies and predicting antimicrobial resistance patterns. Several key genetic factors are likely to play important roles:

• SarA Regulation:

  • The search results clearly demonstrate that sepA is repressed by the global regulator SarA under standard growth conditions .

  • Mutations or variations in sarA or its regulatory elements could lead to increased sepA expression and consequently enhanced biofilm formation and antimicrobial resistance.

  • Analysis of sarA polymorphisms in clinical isolates could provide insights into variations in sepA expression and associated phenotypes.

• Promoter Region Variations:

  • The search results mention a -1A→T mutation in the norA promoter region that coincided with increased norA expression in response to ethidium bromide exposure .

  • Similar mutations in the sepA promoter region could potentially affect its expression levels and response to environmental stimuli.

  • Comprehensive analysis of the sepA promoter region across clinical isolates could identify polymorphisms associated with altered expression patterns.

• Additional Regulatory Elements:

  • While SarA is identified as a repressor of sepA, other regulatory proteins likely also influence its expression.

  • These could include additional global regulators, stress-response systems, or quorum-sensing networks that modulate sepA expression in response to specific environmental conditions.

  • Comparative genomics and transcriptomics of clinical isolates could help identify these additional regulatory elements.

• Structural Variations in SepA:

  • Amino acid substitutions in SepA could affect its substrate specificity, transport efficiency, or proteolytic activity.

  • The search results indicate that sepA sequence variants exist across different Staphylococcal species .

  • Similar variations might exist among different S. epidermidis clinical isolates, potentially leading to functional differences in antimicrobial resistance profiles or biofilm-forming capacity.

• Genetic Context and Mobile Genetic Elements:

  • The genetic context of sepA, including adjacent genes and potential mobile genetic elements, could influence its expression and function.

  • Horizontal gene transfer might contribute to the spread of particular sepA variants or regulatory elements among clinical isolates.

Understanding these genetic factors would provide valuable insights into the variability of sepA-mediated antimicrobial resistance and biofilm formation among clinical S. epidermidis isolates. This knowledge could inform the development of diagnostic tools to predict resistance patterns and guide the selection of appropriate antimicrobial therapies.